Abbott Laboratories agreed to pay nearly $385 million to settle allegations the Lake County-based company made baby formula at an unsanitary plant whose products were recalled as regulators investigated two infant deaths.

Abbott Laboratories has had a rough year in the market, and the recent product news now puts a sharper spotlight on whether the current share price is properly grounded in the cash the business can generate. With a Discounted Cash Flow (DCF) view available, the question is how the recent market drop lines up with the long term cash flow profile investors are effectively paying for today. Over the past year, Abbott Laboratories shares have fallen 23.1%, which puts recent sentiment and the...

Abbott Laboratories (ABT) has been back in focus after rolling out three new FDA-backed products in quick succession, spanning nutrition, digital heart failure management and blood-based colorectal cancer screening. Despite these launches, Abbott Laboratories’ share price has had a mixed run, with a 6.04% 90-day share price return and a weaker year-to-date share price return of a 19.8% decline. The 3-year total shareholder return of 16.03% points to sturdier longer-run momentum than the past...

Barclays set a USD 120.00 target on October 7, 2026. Abbott Laboratories stock costs EUR 88.76 on Oc

SimpleScreen CRC reported 81.10 percent sensitivity. Abbott Laboratories stock costs EUR 89.27 on Oc

Abbott Laboratories is a global health care company. Founded in 1888, the company operates in four main segments: established pharmaceutical products, diagnostic products, nutritional products—including infant formula—and medical devices. As of 2024, Abbott’s medical devices segment was its largest and fastest-growing, accounting for about 45% of revenue. That segment includes devices for monitoring cardiovascular health, glucose monitoring systems for diabetes care, and neuromodulation devices for chronic pain and movement disorders.

Abbott Laboratories stock is EUR 87.75 pre-market at Lang & Schwarz, down 0.33 percent versus the pr

Lang & Schwarz quoted Abbott Laboratories at EUR 88.01 after-hours at 10:00 p.m. CEST on October 8,

Revenue rose 13.00 percent to USD 12.59 billion in the second quarter. Abbott Laboratories stock cos

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

If you only glanced at Abbott Laboratories’ headlines this year, the story looked constructive. Product launches, major diagnostics deals and raised guidance all suggested a business pushing ahead. For Abbott Laboratories shareholders, the loss over the past year was 24.8%, including dividends. If you had been weighing an entry on 7 October 2025, how much of that eventual drawdown was hinted at by the earnings mix, margins and acquisition plans already on the table? A Narrative on Simply Wall...

Abbott Laboratories stock is at EUR 88.06 pre-market at Lang & Schwarz on October 8, 2026, at 8:20 a

The Judicial Panel on Multidistrict Litigation has created separate MDLs over purportedly defective spinal cord stimulators manufactured by Nevro LLC and Abbott Laboratories, rejecting the manufacturers' arguments that the cases' plaintiffs do not share enough common factual questions to warrant consolidation.

In early October 2026, Abbott Laboratories received FDA approval for updates to its CardioMEMS HF System, allowing U.S. heart failure patients to see pulmonary artery pressure readings and receive clinician-guided medication adjustments via the new CardioGuide HF App and Dynamic Treatment Plan on their smartphones. This move deepens Abbott’s push into connected cardiac care by pairing an established implantable sensor with patient-facing digital tools that can support earlier intervention...

Abbott Laboratories stock was trading at USD 97.89 on October 7, 2026, within a USD 81.97 to USD 135